AIMS: Medications play a limited role in the treatment of alcoholism. This paper examines physicians' opinions about and use of two alcoholism medications currently approved in the US--disulfiram and naltrexone--and one alcoholism medication--acamprosate--that might be approved. DESIGN: A total of 1388 substance abuse specialist physicians who were members of the American Academy of Addiction Psychiatry or the American Society of Addiction Medicine completed a questionnaire in 2001 (65% response rate). FINDINGS: The average percentages of physicians' patients with alcoholism who were prescribed the following medications were: 13% (naltrexone), 9% (disulfiram), 46% (antidepressants) and 11% (benzodiazepines). Almost all physicians had heard of naltrexone and disulfiram, but their self-reported level of knowledge about these medications was lower than for antidepressants. Physicians estimated that naltrexone had a small-to-medium effect size, which was similar in magnitude to the effect size reported in recent meta-analyses of randomized clinical trials. Physicians identified the following three courses of action as the most likely to result in greater use of medications to treat alcohol dependence: more research to develop new medications (33%), more education of physicians about existing medications (17%), and increased involvement of physicians in alcoholism treatment (17%). CONCLUSIONS: Physicians' low rate of use of naltrexone may reflect its small-to-medium effect size.
AIMS: Medications play a limited role in the treatment of alcoholism. This paper examines physicians' opinions about and use of two alcoholism medications currently approved in the US--disulfiram and naltrexone--and one alcoholism medication--acamprosate--that might be approved. DESIGN: A total of 1388 substance abuse specialist physicians who were members of the American Academy of Addiction Psychiatry or the American Society of Addiction Medicine completed a questionnaire in 2001 (65% response rate). FINDINGS: The average percentages of physicians' patients with alcoholism who were prescribed the following medications were: 13% (naltrexone), 9% (disulfiram), 46% (antidepressants) and 11% (benzodiazepines). Almost all physicians had heard of naltrexone and disulfiram, but their self-reported level of knowledge about these medications was lower than for antidepressants. Physicians estimated that naltrexone had a small-to-medium effect size, which was similar in magnitude to the effect size reported in recent meta-analyses of randomized clinical trials. Physicians identified the following three courses of action as the most likely to result in greater use of medications to treat alcohol dependence: more research to develop new medications (33%), more education of physicians about existing medications (17%), and increased involvement of physicians in alcoholism treatment (17%). CONCLUSIONS: Physicians' low rate of use of naltrexone may reflect its small-to-medium effect size.
Authors: Stanley S Wallack; Cindy Parks Thomas; Timothy C Martin; Jon Chilingerian; Sharon Reif Journal: J Behav Health Serv Res Date: 2008-07-31 Impact factor: 1.505
Authors: Emily C Williams; Carol E Achtmeyer; Jessica P Young; Douglas Berger; Geoffrey Curran; Katharine A Bradley; Julie Richards; Michael B Siegel; Evette J Ludman; Gwen T Lapham; Mark Forehand; Alex H S Harris Journal: J Gen Intern Med Date: 2017-10-30 Impact factor: 5.128
Authors: Christopher T Rentsch; David A Fiellin; Kendall J Bryant; Amy C Justice; Janet P Tate Journal: Alcohol Clin Exp Res Date: 2019-02-03 Impact factor: 3.455
Authors: Scott E Lukas; David Penetar; Zhaohui Su; Thomas Geaghan; Melissa Maywalt; Michael Tracy; John Rodolico; Christopher Palmer; Zhongze Ma; David Y-W Lee Journal: Psychopharmacology (Berl) Date: 2012-10-16 Impact factor: 4.530